CL2017002904A1 - Métodos y kits para tratar la depresión - Google Patents
Métodos y kits para tratar la depresiónInfo
- Publication number
- CL2017002904A1 CL2017002904A1 CL2017002904A CL2017002904A CL2017002904A1 CL 2017002904 A1 CL2017002904 A1 CL 2017002904A1 CL 2017002904 A CL2017002904 A CL 2017002904A CL 2017002904 A CL2017002904 A CL 2017002904A CL 2017002904 A1 CL2017002904 A1 CL 2017002904A1
- Authority
- CL
- Chile
- Prior art keywords
- kits
- methods
- treatment
- depression
- treat depression
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 abstract 1
- 206010010144 Completed suicide Diseases 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 229960000450 esketamine Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164026P | 2015-05-20 | 2015-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002904A1 true CL2017002904A1 (es) | 2018-04-20 |
Family
ID=57320901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002904A CL2017002904A1 (es) | 2015-05-20 | 2017-11-15 | Métodos y kits para tratar la depresión |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160338977A1 (https=) |
| EP (1) | EP3297618A4 (https=) |
| JP (1) | JP2018515557A (https=) |
| KR (1) | KR20180008634A (https=) |
| CN (1) | CN107735081A (https=) |
| AU (3) | AU2016263598A1 (https=) |
| CA (1) | CA2986477A1 (https=) |
| CL (1) | CL2017002904A1 (https=) |
| CO (1) | CO2017011564A2 (https=) |
| DO (1) | DOP2017000268A (https=) |
| EA (1) | EA201792545A1 (https=) |
| EC (1) | ECSP17077930A (https=) |
| GT (1) | GT201700246A (https=) |
| HK (1) | HK1252937A1 (https=) |
| IL (1) | IL255463A (https=) |
| MA (1) | MA42135A (https=) |
| MX (1) | MX2017014797A (https=) |
| PE (1) | PE20180260A1 (https=) |
| PH (1) | PH12017502103A1 (https=) |
| WO (1) | WO2016187491A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| KR20170040800A (ko) | 2014-08-13 | 2017-04-13 | 얀센 파마슈티카 엔.브이. | 우울증 치료 방법 |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| KR20240011237A (ko) * | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| BR112020023882A2 (pt) * | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| WO2020070547A1 (en) * | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| CN112702995A (zh) * | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| JP2022524008A (ja) * | 2019-03-05 | 2022-04-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のためのエスケタミン |
| CN114286674A (zh) * | 2019-08-28 | 2022-04-05 | 杨森制药公司 | 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮 |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| JP7840873B2 (ja) * | 2020-05-28 | 2026-04-06 | ヤンセン ファーマシューティカ エヌ．ベー． | うつ病の治療方法 |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| WO2022235576A1 (en) * | 2021-05-03 | 2022-11-10 | Wang Michael Z | Methods and compositions for treating depression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013003669A2 (en) * | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| WO2013138322A1 (en) * | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| EP2830604A4 (en) * | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
| DK2983787T3 (da) * | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| AU2015318123A1 (en) * | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
-
2016
- 2016-05-19 US US15/159,257 patent/US20160338977A1/en not_active Abandoned
- 2016-05-20 EA EA201792545A patent/EA201792545A1/ru unknown
- 2016-05-20 HK HK18112292.0A patent/HK1252937A1/zh unknown
- 2016-05-20 AU AU2016263598A patent/AU2016263598A1/en not_active Abandoned
- 2016-05-20 CA CA2986477A patent/CA2986477A1/en not_active Abandoned
- 2016-05-20 JP JP2017560314A patent/JP2018515557A/ja active Pending
- 2016-05-20 KR KR1020177036002A patent/KR20180008634A/ko not_active Withdrawn
- 2016-05-20 PE PE2017002425A patent/PE20180260A1/es unknown
- 2016-05-20 CN CN201680029082.XA patent/CN107735081A/zh active Pending
- 2016-05-20 WO PCT/US2016/033404 patent/WO2016187491A1/en not_active Ceased
- 2016-05-20 MX MX2017014797A patent/MX2017014797A/es unknown
- 2016-05-20 MA MA042135A patent/MA42135A/fr unknown
- 2016-05-20 EP EP16797348.6A patent/EP3297618A4/en not_active Withdrawn
-
2017
- 2017-11-06 IL IL255463A patent/IL255463A/en unknown
- 2017-11-14 CO CONC2017/0011564A patent/CO2017011564A2/es unknown
- 2017-11-15 CL CL2017002904A patent/CL2017002904A1/es unknown
- 2017-11-16 GT GT201700246A patent/GT201700246A/es unknown
- 2017-11-17 DO DO2017000268A patent/DOP2017000268A/es unknown
- 2017-11-20 PH PH12017502103A patent/PH12017502103A1/en unknown
- 2017-11-23 EC ECIEPI201777930A patent/ECSP17077930A/es unknown
-
2021
- 2021-08-11 AU AU2021215155A patent/AU2021215155A1/en not_active Abandoned
-
2023
- 2023-09-25 AU AU2023237026A patent/AU2023237026A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016263598A1 (en) | 2017-11-23 |
| GT201700246A (es) | 2019-07-29 |
| IL255463A (en) | 2018-01-31 |
| KR20180008634A (ko) | 2018-01-24 |
| JP2018515557A (ja) | 2018-06-14 |
| EA201792545A1 (ru) | 2018-05-31 |
| ECSP17077930A (es) | 2018-02-28 |
| PE20180260A1 (es) | 2018-02-05 |
| CO2017011564A2 (es) | 2018-04-19 |
| DOP2017000268A (es) | 2018-04-15 |
| US20160338977A1 (en) | 2016-11-24 |
| HK1252937A1 (zh) | 2019-06-06 |
| EP3297618A1 (en) | 2018-03-28 |
| PH12017502103A1 (en) | 2018-05-07 |
| AU2021215155A1 (en) | 2021-09-02 |
| CA2986477A1 (en) | 2016-11-24 |
| AU2016263598A8 (en) | 2017-11-30 |
| AU2023237026A1 (en) | 2023-10-12 |
| EP3297618A4 (en) | 2019-01-23 |
| WO2016187491A1 (en) | 2016-11-24 |
| MA42135A (fr) | 2018-03-28 |
| CN107735081A (zh) | 2018-02-23 |
| MX2017014797A (es) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002904A1 (es) | Métodos y kits para tratar la depresión | |
| CL2018003588A1 (es) | Uso de inhibidores de miostatina y terapias de combinación. | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2018003213A1 (es) | Inhibidores enzimáticos. | |
| CL2017003006A1 (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| CL2017003005A1 (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| MX2017007256A (es) | Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer. | |
| BR112018008882A8 (pt) | método para tratar um distúrbio proliferativo e produto farmacêutico | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
| BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
| BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2023007405A (es) | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| CO2017002356A2 (es) | Métodos para tratar la depresión usando moduladores de nmda | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
| AR105701A1 (es) | Métodos y estuches para tratar la depresión | |
| MX2020004731A (es) | Terapias de combinacion de inhibidor ezh2. | |
| AR109858A1 (es) | Métodos que usan inhibidores hdac11 |